Blame ministers for AstraZeneca U-turn
Re Nils Pratley's column (AstraZeneca's £450m Speke U-turn looks terrible for a pro-growth government, 3 February), when I was minister of health from 1974 to 1976 under Barbara Castle as secretary of state, I was the sponsoring minister for the pharmaceutical industry, a responsibility I took very seriously. Despite a very heavy national workload, I travelled to Brazil and Russia to promote the industry, and had as an adviser a former chief executive of a pharmaceutical company.
Losing AstraZeneca's £450m investment in Liverpool would have been impossible in this ministerial structure that was very close to the industry. The present ministerial decision-making structure is clearly incoherent.David OwenLondon
Have an opinion on anything you've read in the Guardian today? Please email us your letter and it will be considered for publication in our letters section.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
12 hours ago
- Daily Mail
That's Nice! Informa chiefs swan off on Riviera junket
The entire board of Informa will de-camp to the sun-drenched French Riviera this week for its annual meeting as the publisher becomes the latest London-listed company to deter shareholders from turning up to such events in person. Informa's move means its annual meeting will in effect be online-only for UK-based share owners as they would struggle to find the time – and in some cases the money – to attend. It would cost the best part of £1,000 in flights and accommodation to go to the meeting, held at the five-star Maison Albar hotel in the heart of Nice. Informa joins the likes of drugs giant AstraZeneca, defence contractor BAE Systems and toothpaste-maker Haleon in moving their annual meeting to what amounts to a digital-only format. Campaigners say firms are doing this to stifle scrutiny, debate and dissent in a blow to shareholder democracy. Catherine Howarth, head of small investor lobby group ShareAction, said Informa's migration to the balmy climes of the Cote d'Azur was another example of 'disappearing directors', adding: 'Its decision not to make the board available to shareholders in the usual way this year confirms a growing pattern of disregard for shareholder accountability and access.' She urged the Government and regulators to 'take steps to stop this pattern in its tracks'. Another shareholder described Informa's decision as 'incredible', while a third expressed surprise – not least because last year's in-person event in London was 'jam-packed' and 'one of the best I've ever attended'. The FTSE 100 company has been rocked by shareholder revolts over boardroom pay. Stephen Carter, a former chief adviser to Gordon Brown as Prime Minister, has earned almost £40 million since becoming chief executive in 2013. He could net £7.2 million this year – a fifth more than the £5.9 million he took home in 2024. Carter, who was the founding boss of communications regulator Ofcom before entering Downing Street, has presided over the rapid expansion of Informa into the world's largest business events group, lifting its stock market value to more than £10 billion. It also owns academic publisher Taylor & Francis. Last year Informa snapped up France's Ascential in a £1.2 billion deal that brought a prestigious advertising jamboree called Cannes Lions into its fold. Chairman John Rishton told investors the meeting was being held in nearby Nice 'to enable the board to attend' the festival, which is now Informa's largest single event and also takes place this week. He added: 'We are delighted to welcome shareholders to attend in person in France.' They are more likely to watch online, as one night at the hotel costs £765, breakfast included, while a return flight from Gatwick is at least another £87. Company law is unclear about where and in what form annual meetings should take place, as the legislation was drawn up 20 years ago, before staging virtual events became common. Meetings must be in a physical location but it is not stipulated if it has to be in the UK, if the board must be present or investors must be let in. Ministers are consulting on the issue. Firms argue that face-to-face meetings are costly to stage and can be disrupted by protesters – as happened recently at Drax when environmental activists forced the energy generator's meeting to end early. Some companies have gone back to a 'hybrid' format under pressure from shareholders. They include Marks & Spencer, which was accused of being 'arrogant' and setting 'an appalling precedent' after trying to make its meeting online-only. Informa said it 'would expect to return' to London for next year's AGM.
Daily Mail
a day ago
- Daily Mail
AstraZeneca in deal with China firm worth up to £4bn
AstraZeneca has agreed a deal that could be worth almost £4billion with a Chinese company to use AI in the production of new treatments for chronic diseases. Britain's largest listed company announced the tie-up with biotech firm CSPC Pharmaceuticals following controversy over its involvement in China. The pharmaceuticals giant will pay CSPC an upfront fee of £81m while a total further payment of up to £3.8billion is available if the drugs reach development and sales-related milestones. AstraZeneca has been ploughing cash into the country, including announcing a £1.8billion research and development hub in the capital Beijing. The firm's former boss in China, Leon Wang, was arrested in October and is still thought to be in detention. More recently, former Tory leader Sir Iain Duncan Smith has accused the pharma giant of 'turning a blind eye to the nature of the Chinese government'. AstraZeneca boss Sir Pascal Soriot said in February: 'We all think about Leon and miss him, but the reality is we are not able to talk to him. We are not allowed.'
Reuters
2 days ago
- Reuters
AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC
June 13 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Friday it has agreed to a research deal with Chinese drugmaker CSPC Pharmaceuticals ( opens new tab worth up to $5.22 billion to focus on AI-enabled initiatives.
